Aspire Biopharma Holdings (ASBP) Accounts Payables (2021 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Accounts Payables of $857925.0 for Q1 2026, down 40.09% year-over-year from $1.4 million in Q1 2025, and down 15.42% quarter-over-quarter from $1.0 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Accounts Payables (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Accounts Payables for 6 consecutive years, with $857925.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 40.09% year-over-year to $857925.0; the TTM figure through Mar 2026 stood at $857925.0 (down 40.09% YoY), while the FY2025 annual figure was $1.0 million, up 226.99% from the prior year.
- Accounts Payables declined to $857925.0 in Q1 2026 per ASBP's latest filing, from $1.0 million in the prior quarter.
- Across five years, Accounts Payables topped out at $1.4 million in Q1 2025 and bottomed at $19067.0 in Q1 2022.
- Historically, Accounts Payables has averaged $494839.9 across 5 years, with a median of $256975.5 in 2023.
- Annual changes were most pronounced in 2022 — Accounts Payables soared 66066.3% — and 2026, when it sank 40.09%.
- Aspire Biopharma Holdings' Accounts Payables stood at $180634.0 in 2022, then fell by 15.85% to $152005.0 in 2023, then surged by 104.08% to $310219.0 in 2024, then soared by 226.99% to $1.0 million in 2025, then retreated by 15.42% to $857925.0 in 2026.
- Business Quant data shows ASBP's Accounts Payables at $857925.0 in Q1 2026, $1.0 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | 972,108.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 972,108.00 |
| Mar 31, 2026 | 857,925.00 |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.43 Mn |
| Dec 31, 2024 | 310,219.00 |
| Jun 30, 2024 | 584,078.00 |
| Mar 31, 2024 | 365,010.00 |
| Dec 31, 2023 | 152,005.00 |
| Sep 30, 2023 | 104,379.00 |
| Jun 30, 2023 | 101,667.00 |
| Mar 31, 2023 | 203,732.00 |
| Dec 31, 2022 | 180,634.00 |
| Sep 30, 2022 | 96,016.00 |
| Jun 30, 2022 | 83,777.00 |
| Mar 31, 2022 | 19,067.00 |
| Dec 31, 2021 | 273.00 |